Development of the membrane autotransfusion system prototype-II: MATS-II.
This article is the second of a two-part series describing a membrane autotransfusion system, MATS, utilizing plasmapheresis technology. Based on experiences obtained from the first prototype (MATS-I), optimum blood filtration parameters with refined blood and flux pump synchronization were put into an original CPU-board and loaded on a miniaturized, self-operative, and preclinical prototype (MATS-II). This study was conducted to evaluate the MATS-II using diluted blood of various hematocrit concentrations. The results proved that this device could concentrate 4,000-10,000 ml of various hematocrit concentrations into higher than 40% while automatically controlling the flow speed from 250 to 400 ml/min. Also, no significant damage was generated to the red blood cells (RBC). Moreover, the MATS-II salvaged over 90% of platelets together with the RBC. These results suggest that the MATS-II achieves all clinical requirements of an autotransfusion device; it is a continuous hemoconcentration device with minimum damage to cellular components of the blood.
Fukunaga
K
K
Department of Internal Medicine IV, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Shimoyama
T
T
Sawada
K
K
Sueoka
A
A
Nosé
Y
Y
D000818:Animals; D001783:Blood Flow Velocity; D001792:Blood Platelets / Q000166:cytology; D001804:Blood Transfusion, Autologous / Q000295:instrumentation*; D001810:Blood Volume; D002417:Cattle; D004209:Disposable Equipment; D004867:Equipment Design; D004912:Erythrocytes / Q000166:cytology; D006400:Hematocrit; D006438:Hemodilution; D006440:Hemofiltration / Q000295:instrumentation; D006461:Hemolysis; D013677:Medical Laboratory Science / Q000295:instrumentation; D008567:Membranes, Artificial; D008904:Miniaturization; D010956:Plasmapheresis / Q000295:instrumentation
D008567:Membranes, Artificial